Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
262.76B
Market cap262.76B
Price-Earnings ratio
16.77
Price-Earnings ratio16.77
Dividend yield
2.65%
Dividend yield2.65%
Average volume
2.09M
Average volume2.09M
High today
$125.46
High today$125.46
Low today
$123.45
Low today$123.45
Open price
$123.45
Open price$123.45
Volume
1.37M
Volume1.37M
52 Week high
$133.55
52 Week high$133.55
52 Week low
$96.06
52 Week low$96.06

NVS News

TipRanks 1d
Cautious Hold on Novartis AG Amid Mixed Ianalumab Data and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novartis AG, retaining the price target of CHF111.00. Elevate Your Investing Strat...

The Motley Fool 5d
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Novartis is set to boost its developmental pipeline with this acquisition. Shares in Avidity Biosciences (RNA +0.01%) soared by 42% in the week to Friday morni...

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
TipRanks 5d
Novartis upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Novartis (NVS) to Overweight from Equal Weight with a price target of CHF 110, up from CHF 108. The firm cites valuation for the upgrade...

Analyst ratings

59%

of 27 ratings
Buy
22.2%
Hold
59.3%
Sell
18.5%

More NVS News

TipRanks 5d
Positive Long-Term Growth Outlook for Novartis AG Amid Temporary Setbacks

In a report released today, Thibault Boutherin from Morgan Stanley upgraded Novartis AG to a Buy, with a price target of CHF110.00. Elevate Your Investing Strat...

TipRanks 7d
Novartis reports NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective

Novartis (NVS) presented new ianalumab data in Sjogren’s disease at a late-breaker presentation during the American College of Rheumatology Convergence congress...

TipRanks 7d
Novartis AG Reports Strong Q3 2025 Earnings Growth

Novartis AG ( (NVS) ) has released its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Elevate Your Investing Strat...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.